> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Review Glaxo Trelegy Ellipta sNDA
- URL: https://www.fdaweb.com/panel-to-review-glaxo-trelegy-ellipta-snda/
- Published: 2020-02-19T12:00:00.000Z
- Updated: 2026-09-14T16:03:44.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5146120

*Federal Register* notice: FDA has announced a 4/21 Pulmonary-Allergy Drugs Advisory Committee meeting. Panel members are scheduled to discuss a GlaxoSmithKline supplemental NDA for Trelegy Ellipta, a fixed-dose combination (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) oral inhalation for reducing all-cause mortality in patients with chronic obstructive pulmonary disease (COPD). The panel will focus on discussing efficacy data submitted to support the proposed labeling claim, including the results from the Informing the Pathway of COPD Treatment (IMPACT) trial and the influence of inhaled corticosteroids withdrawal on the results. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-03410.pdf?ref=fdaweb.com).